Video Interview: Roche Doubles Down On Immuno-Oncology Trial Collaborations
This article was originally published in Scrip
Roche partnering exec Jason Coloma explains his company's approach to developing the next wave of immuno-oncology therapies, through collaborations. In the fast-paced, high value world of immuno-oncology development, the number of potential combinations of therapies, including doublet and triplet regimens, is enormous.Recognizing that means you won't have everything in-house and will need to establish external collaborations with a wide range companies, Coloma explains to Emily Hayes, senior editor at Scrip's sister publication, "The Pink Sheet".
Register for our free email digests: